SEC 13F Intelligence

Managers / Q4 2020 · view latest →

Camber Capital Management LP

CIK 0001444043 · 101 HUNTINGTON AVENUE, SUITE 2101, BOSTON, MA, 02199 · 617-717-6600

Reported Value
$2.8B
Q4 2020
Positions
33
Filings on Record
28
2019–present window
Filed
Feb 16, 2021
original filing

Summary

Camber Capital Management LP reported $2.8B in U.S.-listed holdings across 33 positions for Q4 2020.

Its largest position, CHNGUSD, represents 8.5% of the portfolio.

Compared with Q3 2020, the fund opened 6 new positions and exited 10.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $2.1BQ4 ’18Q1 ’19: $2.0BQ2 ’19: $2.1BQ3 ’19: $1.9BQ4 ’19: $2.0BQ4 ’19Q1 ’20: $1.7BQ2 ’20: $1.7BQ3 ’20: $1.9BQ4 ’20: $2.8BQ4 ’20Q1 ’21: $2.9BQ2 ’21: $3.0BQ3 ’21: $3.2BQ4 ’21: $2.9BQ4 ’21Q1 ’22: $2.8BQ2 ’22: $2.3BQ3 ’22: $3.3BQ1 ’23: $3MQ1 ’23Q2 ’23: $3MQ3 ’23: $3MQ4 ’23: $4MQ1 ’24: $4MQ1 ’24Q2 ’24: $4MQ3 ’24: $3MQ4 ’24: $4MQ2 ’25: $1.1BQ2 ’25filingsflow.com

Portfolio Composition

By security type
Common Stock: 81.8%Other: 16.7%ADR: 1.5%
  • Common Stock · 81.8% · $2.3B
  • Other · 16.7% · $476M
  • ADR · 1.5% · $43M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2020 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
VTRSVIATRIS INCNEW+12.00M12.00M+$225M$225M
WBAWALGREENS BOOTS ALLIANCE INCNEW+4.00M4.00M+$160M$160M
GILDGILEAD SCIENCES INCNEW+2.50M2.50M+$146M$146M
BMYBRISTOL-MYERS SQUIBB CONEW+2.00M2.00M+$124M$124M
ABBVABBVIE INCNEW+1.00M1.00M+$107M$107M
BIIBBIOGEN INCNEW+200.0K200.0K+$49M$49M
ANGOANGIODYNAMICS INCADDED+519.5K540.4K+$8M$8M
GLAXOSMITHKLINE PLCADDED+3.05M3.50M+$112M$129M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2020

28 positions
#IssuerClass% PortfolioValueShares
1CHNGUSDCHANGE HEALTHCARE INCCOM8.51%$242M13.00M
2VTRSVIATRIS INCCOM7.89%$225M12.00M
3UHSUNIVERSAL HLTH SVCS INCCL B6.76%$193M1.40M
4ALXNALEXION PHARMACEUTICALS INCCOM6.44%$184M1.18M
5HCAHCA HEALTHCARE INCCOM4.91%$140M850.0K
6ALKERMES PLCSHS4.73%$135M6.75M
7PERRIGO CO PLCSHS4.71%$134M3.00M
8GLAXOSMITHKLINE PLCSPONSORED ADR4.52%$129M3.50M
9THCTENET HEALTHCARE CORPCOM NEW4.20%$120M3.00M
10WBAWALGREENS BOOTS ALLIANCE INCCOM4.20%$120M3.00M
11MYGNMYRIAD GENETICS INCCOM3.47%$99M5.00M
12BHCBAUSCH HEALTH COS INCCOM3.10%$88M4.25M
13IRWDIRONWOOD PHARMACEUTICALS INCCOM CL A3.00%$85M7.50M
14SRPTSAREPTA THERAPEUTICS INCCOM2.39%$68M400.0K
15B7SBROOKDALE SR LIVING INCCOM1.90%$54M12.20M
16BIIBBIOGEN INCCOM1.72%$49M200.0K
17AVROBIO INCCOM1.53%$44M3.13M
18TEVATEVA PHARMACEUTICAL INDS LTDSPONSORED ADS1.52%$43M4.50M
19NKTREURNEKTAR THERAPEUTICSCOM1.49%$43M2.50M
20COLLCOLLEGIUM PHARMACEUTICAL INCCOM1.41%$40M2.00M
21CHRSCOHERUS BIOSCIENCES INCCOM1.34%$38M2.20M
22RDUSEURRADIUS HEALTH INCCOM NEW1.30%$37M2.08M
23BLUEBIRD BIO INCCOM1.21%$35M800.0K
24EP3ORASURE TECHNOLOGIES INCCOM1.21%$34M3.25M
25PBYIPUMA BIOTECHNOLOGY INCCOM0.92%$26M2.56M
26DRNAUSDDICERNA PHARMACEUTICALS INCCOM0.41%$12M525.0K
27ANGOANGIODYNAMICS INCCOM0.29%$8M540.4K
28GLYCEURGLYCOMIMETICS INCCOM0.29%$8M2.20M

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q2 2025$1.1B25Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025under review32May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$4M39Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$3M33Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$4M37Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$4M36May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$4M38Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$3M40Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$3M38Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$3M41May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022under review39Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$3.3B45Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$2.3B40Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$2.8B37May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$2.9B39Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$3.2B39Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$3.0B34Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$2.9B32May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$2.8B33Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$1.9B35Nov 16, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$1.7B30Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$1.7B29May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$2.0B29Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$1.9B34Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$2.1B31Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$2.0B28May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$2.1B36Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.